Metabolic Labeling Methods 227
227
19
Metabolic Labeling Methods for the Preparation
and Biosynthetic Study of Mucin
Anthony P. Corfield, Neil Myerscough, B. Jan-Willem Van Klinken,
Alexandra W. C. Einerhand, and Jan Dekker
1. Introduction
Radiolabeling methods have been introduced into the study of the biology of mucin
for several reasons (1–3). In many instances, the biochemical analysis of mucins in
any form may be limited owing to the small amounts of mucosal tissue available, of
cells from culture systems, and the difficulty in obtaining normal material for com-
parison (3–6). The use of radiolabeling in direct assessment of the biochemistry of the
metabolism of mucins, in particular their biosynthesis, is well suited to these tech-
niques in the same way they have been adopted for other proteins and glycoconjugates.
It is currently of special interest in evaluating the different stages in the maturation,
aggregation, and secretion of mucin.
Separation methods for mucins have relied on the properties of these molecules,
typically their buoyant density on density gradients, high molecular weight on gel
filtration, their charge on ion-exchange chromatography and combination of molecu-
lar size and charge on agarose gel electrophoresis (7–10). These methods have been
applied to microscale radiolabelled mucins (2,3), and to larger amounts of mucins
from cell culture or resected tissue (3,11, see Chapters 1, 2, and 7). Although these
separations yield pure fractions of mucin in most cases, contamination with proteo-
glycans and nucleic acids needs to be controlled. Identification and elimination of
these contaminants may be necessary depending on the data on the mucin required.
This chapter describes the methods to radioactively tag mucins by metabolic label-
ling. Since these techniques require living, mucins producing cells, they will closely
follow the protocols for optimal cell and tissue culture as described in Chapter 18.
Continuous culture (4–96 h) of cell lines or tissue in the presence of radiolabeled
monosaccharides, amino acids, or sulfate will lead to the accumulation of radioac-
tively labeled mature mucins in the cells and the culture medium. This chapter further
concentrates on the subsequent isolation and detailed analysis of these mature mucins.
From:
Methods in Molecular Biology, Vol. 125: Glycoprotein Methods and Protocols: The Mucins
Edited by: A. Corfield © Humana Press Inc., Totowa, NJ
228 Corfield et al.
However, the possibilities of metabolic labeling to study minute amounts of mucin
can also be applied to the mucin precursors, i.e., to the biosynthesis of the mucin
polypeptide and other early steps in mucin biosynthesis such as N-glycosylation and
early O-glycosylation. In addition, the dynamics of each step during synthesis and
secretion can be studied. Experiments to identify mucin precursors and the dynamics
of processing steps require short labeling periods (15–60 min), referred to as pulse
labeling, and ensuing incubations to follow the processing of the labeled molecules
with time (4–6 h), referred to as chase incubations. Since these mucin precursors are
present in only very small amounts relative to the mature mucin, the isolation of these
biosynthetic intermediates requires immunoprecipitation, which is described in Chap-
ters 20 and 21.
2. Materials
1. A source of mucin-producing cells. These can be biopsies, explants or cell lines as
described in Chapter 18.
2. Radioactively labelled precursors:
a. L-(
35
S)methionine/L-(
35
S)cysteine, (Promix™, Amersham, Amersham, UK), a mix-
ture containing 65% (
35
S)methionine and 25% (
35
S)cysteine, specific activity 1000
Ci/mmol (37,000 GBq/mmol), concentration 10 mCi/mL (370 MBq/mL).
b. L-(
3
H)threonine (Amersham): specific activity 5–20 Ci/mmol (185–740 GBq/mmol),
concentration is 1 mCi/mL (37 MBq/mL).
c. D-(6-
3
H)galactose (Amersham): specific activity 20–40 Ci/mmol (740–480 GBq/
mmol), concentration is 1 mCi/mL (37 MBq/mL).
d. D-(
3
H)glucosamine (Amersham): specific activity 20–40 Ci/mmol (740 GBq/mmol),
concentration is 1 mCi/mL (37 MBq/mL).
e. Sodium (
35
S)sulfate (in aqueous solution, code SJS-1; Amersham) specific activity
1050 Ci/mmol (38,850 GBq/mmol), concentration 2 mCi/mL (74 MBq/mL).
3. Media for metabolic pulse-labeling (15–60 min):
a. Eagle’s minimal essential medium (EMEM) (Gibco-BRL, Paisley, Scotland) without
L-methionine and L-cysteine for labeling with Promix (see item 2a), supplemented
with nonessential amino acids, 100 IU/mL of penicillin, 100 µg/mL of streptomycin,
and 2 mM of L-glutamine.
b. EMEM without L-threonine (Gibco/BRL), supplemented with nonessential amino
acids, 100 IU/mL of penicillin, 100 µg/mL of streptomycin, and 2 mM of L-glutamine.
c. EMEM with low glucose (Gibco/BRL), (50 mg/mL instead of 1000 mg/mL) for la-
beling with D-(6-
3
H)galactose, supplemented with nonessential amino acids, 100 IU/
mL of penicillin, 100 µg/mL of streptomycin, and 2 mM of L-glutamine.
d. EMEM without sulfate for labeling with (
35
S)sulfate supplemented with nonessential
amino acids, 100 IU/mL of penicillin, 100 µg/mL of streptomycin, and 2 mM of L-
glutamine. This medium is not available commercially, and all compounds are recon-
stituted from concentrated stock solutions (Gibco/BRL) except that MgSO
4
is replaced
with an equimolar solution of MgCl
2
. Streptomycin should also be avoided because
this is supplied as the sulfate form.
4. Medium for chase incubations: standard EMEM (Gibco/BRL) supplemented with nones-
sential amino acids, 100 IU/mL of penicillin, 100 µg/mL of streptomycin, and 2 mM of L-
glutamine.
5. Guanidine hydrochloride, approx 7 M stock solution, prepared as follows:
Metabolic Labeling Methods 229
a. Dissolve guanidine hydrochloride (grade 1; Sigma, Poole, UK) in high purity (e.g.,
Milli Q) water or phosphate-buffered saline (PBS) to give a concentration of approx 7
or 8 M and stir for 24 h at room temperature.
b. Add 10 g/L of activated charcoal and stir at 4°C for 24 h.
c. Filter through two layers of Whatman No. 1 filter paper.
d. Add a further 10 g/L of activated charcoal, stir overnight at room temperature.
e. Filter through two layers of Whatman No. 1 filter paper and then pass through 0.2-µm
Millipore filter (three times).
f. Monitor the concentration by refractive index.
6. Dithiothreitol (DTT) (Sigma).
7. Sodium iodoacetamide (Sigma).
8. PBS/inhibitor cocktail in PBS and 6 M guanidine hydrochloride. 1 mM of phenyl-
methylsulfonylfluoride (PMSF), 5 mM of EDTA, 0.1 mg/mL of soybean trypsin inhibitor
(STI), 5 mM of N-ethylmaleimide, 10 mM of benzamidine, and 0.02% of sodium azide.
Prepare inhibitor cocktail fresh as required. This solution is made up from stocks of con-
centrated guanidine hydrochloride as in item 5.
9. Cesium chloride (CsCl) (Sigma).
10. Sepharose CL-2B (Pharmacia, Milton Keynes, UK). Use 1 × 30 cm or 2.5 × 80 cm in all-glass
columns equilibrated in 4 M guanidine hydrochloride/PBS or 10 mM Tris-HCl, pH 8.0.
11. Agarose gels for electrophoresis, 0.8 or 1% (w/v). Agarose (SeaKem LE agarose,
Flowgen, Sittingbourne, UK) is made up at 0.8 or 1% in the running buffer. Gels 15 × 15
cm are run in a standard submarine horizontal electrophoresis apparatus.
12. Buffers for electrophoresis and vacuum blotting.
a. Running buffer for agarose gel electrophoresis: 40 mM Tris-acetate 1 mM EDTA, pH
8.0, containing 0.1% of sodium dodecyl sulfate (SDS) (add from 10% SDS stock).
b. Sample buffer for agarose gel electrophoresis: 40 mM Tris -acetate 1 mM EDTA, pH
8.0, containing 0.1% of SDS with 10% of glycerol and 1% of bromophenol blue.
c. Vacuum-blotting buffer: 3.3 M sodium citrate, pH 7.0, containing 3 M NaCl.
13. Markers for electrophoresis; Rainbow markers, high molecular weight range (Amersham),
maximum 200 kDa (myosin) and IgM, 990 kDa (Sigma).
14. Immobilon P (polyvinyldene difluoride, PVDF) membrane (Millipore, Watford, UK).
15. High molecular weight (>20 kDa) polyethylene glycol, PEG 20,000 (Sigma)
16. Periodic acid-Schiff reagent (PAS) commercial solution (Sigma).
17. Precipitation buffer: 95% ethanol/1% sodium acetate cooled to –70°C.
18. Proteoglycan degrading enzymes and incubation buffers. Protease inhibitors may be
included in the incubation buffers (see Notes 1 and 2).
a. Chondroitinase ABC from Proteus vulgaris (Boehringer Mannheim, Lewes, UK). In-
cubation buffer: 250 mM Tris-HCl, 176 mM sodium acetate, 250 mM sodium chlo-
ride, pH 8.0.
b. Hyaluronidase from bovine testis (Sigma). Incubation buffer: PBS.
c. Heparinase types II and III from Flavobacterium heparinum, (Sigma), Incubation
buffer: 5 mM sodium phosphate, 200 mM NaCl, pH 7.0.
19. Sephadex G100 (Pharmacia, Milton Keynes, UK). Use 30 × 1 cm all-glass columns equili-
brated and run in 10 mM of Tris-HCl, pH 8.0.
20. Ultraturrax homogenizer (Jahnke and Kunkel, Stauffen, Germany).
21. Ultracentrifuge routinely capable of 100,000g for up to 72 h.
230 Corfield et al.
3. Methods
3.1. Metabolic Labeling
3.1.1. Continuous Labeling of Mature Mucins (
see
Notes 1 and 2)
3.1.1.1. C
ONTINUOUS
L
ABELING
U
SING
G
ASTROINTESTINAL
(GI) C
ELLS
1. Cells are cultured in standard growth medium as described in Chapter 18.
2. Radioactive precursors (Subheading 2., item 2) are added: D-(
3
H)glucosamine, 370–1850
kBq, L-(
3
H)threonine, 370–1850 kBq, (
35
S)sulphate 185–1850 kBq (see Notes 3–5).
3. Cells are incubated under standard conditions for 4–96 h.
3.1.1.2. C
ONTINUOUS
L
ABELING
U
SING
GI T
ISSUE
1. Culture tissue samples on grids with standard growth medium under conditions described
in Chapter 18.
2. Add radioactive precursors: D-(
3
H)glucosamine, 370–740 kBq, L-(
3
H)threonine, 370–
740 kBq or (
35
S)sulphate 925 kBq. In dual labelling experiments the ratio (
3
H):(
35
S) 370
kBq:925 kBq is used with colonic tissue (see Notes 3–5).
3. Incubate biopsies and explants for up to 24 h under standard conditions described in
Chapter 18.
3.1.2. Pulse/Chase Labeling of Mucin Precursors and Mature Mucins
3.1.2.1. P
ULSE
/C
HASE
L
ABELING
U
SING
C
ELL
L
INES
, P
ARTICULARLY
LS174T, C
ACO
-2,
AND
A431
1. Culture cells as described in Chapter 18.
2. Remove the medium and wash the cells with sterile PBS at 37°C and apply the appropri-
ate medium (EMEM) lacking the compound to be used as precursor (Subheading 2.,
item 3). Incubate for 45 min.
3. Add the radioactively labeled compound for 30–60 min (Note 6).
4. Remove the medium containing the label, wash in sterile PBS at 37°C and add standard
EMEM (Subheading 2., item 4).
5. Incubate for 1–20 h.
3.1.2.2. P
ULSE
/C
HASE
L
ABELING
U
SING
GI T
ISSUE
1. Use the submerged technique for tissue culture (Chapter 18). Place the tissue segments (one
per tube) immediately after excision in the appropriate EMEM to deplete the compound to
be used as label. Incubate for 30 min in 100 µL per tube to deplete this compound.
2. Add 100 µCi (3700 kBq) of the radioactive compound and incubate for 15–60 min (see Note 9).
3. Remove the medium containing the label. Wash the tissue once in 500 µL of EMEM at
37°C (Subheading 2., item 4).
4. Add 500 µL of EMEM at 37°C per test tube, and chase incubate for maximally 6 h.
5. After pulse labeling or chase incubation, homogenize the tissue for immunoprecipitation
to allow immunoisolation of mucins, as described in Chapter 20.
3.2. Collection of Secreted and Cellular Material
3.2.1. Collection of Radioactive Fractions
After Metabolic Labeling in Cell Culture (
see
Note 1)
1. Collect the medium and wash the cells with a further 5 mL of fresh nonradioactive me-
dium. Medium and washings are combined and mixed 1:1 (v/v) with 6 M guanidine/PBS
inhibitor cocktail (Subheading 2., items 5 and 8).
Metabolic Labeling Methods 231
2. Irrigate the flasks with 5 mL of 6 M guanidine hydrochloride in PBS/inhibitor cocktail
(see Note 1) containing 10 mM DTT at room temperature, and scrape the cells off with a
cell scraper.
3. Wash the cells twice with 6 M guanidine hydrochloride PBS/inhibitor cocktail containing
10 mM DTTl. Collect the cells by low-speed centrifugation and pool the total washings.
4. Adjust the DTT washings to a 2.5X molar excess with sodium iodoacetamide and incu-
bate for 15 h at room temperature in the dark (see Note 10).
5. Dialyze the medium and DTT wash material extensively at room temperature against
three changes of 6 M guanidine hydrochloride in PBS.
6. Homogenize the washed cell pellet in 1 mL of 6 M guanidine hydrochloride PBS/inhibi-
tor cocktail with an Ultraturrax for 10 s at maximum setting, on ice.
7. Centrifuge the homogenate at 100,000g for 60 min, and decant the supernatant. Resuspend
the membrane fraction in 1 mL of 6 M guanidine hydrochloride PBS/inhibitor cocktail.
3.2.2. Collection of Radioactive Fractions
After Metabolic Labeling in Organ Culture. (
see
Note 3)
1. After incubation, remove the medium from the central well and wash the tissue and dish
with 1 mL of PBS. Pool the medium and washings, and dialyze against three changes of 1 L
of 6 M guanidine hydrochloride PBS over 48 h at room temperature (see Note 2).
2. Homogenize the tissue on ice in 1 mL of PBS/inhibitor cocktail or 6 M guanidine hydro-
chloride PBS/inhibitor cocktail in an all-glass Potter homogenizer, ensuring complete
disruption of the mucosal cells (about 20 strokes). Remove connective tissue, if present,
which resists disruption and sediments as large fragments.
3. Centrifuge the homogenate at 12,000g for 5 min at 4°C, and separate the supernatant
soluble fraction from the membrane pellet.
4. Resuspend the membrane pellet in 1 mL of 6 M guanidine hydrochloride PBS/inhibitor
cocktail.
3.3. Separation of Mucins from the Fractions Obtained
After Culture (
see
Note 11)
3.3.1. Density Gradient Centrifugation
1. Make up the samples from the fractions prepared according to Subheadings 3.2.1.–
3.2.2. in 4 M guanidine hydrochloride/PBS to a concentration of approx 1–5 mg/mL
related to protein concentration, or containing a suitable amount of radioactivity (e.g.,
>10,000 cpm) for subsequent analytical techniques. Add solid CsCl to give a density
of about 1.4 g/mL, and stir at room temperature for 15 h.
2. Load the samples into centrifuge tubes and centrifuge at 100,000 g for at least 48 h at
10°C to obtain a CsCl density gradient.
3. Aspirate 0.5-mL samples from the top of the tube by pipet, or drain from the bottom
after piercing the tubes. Weigh the samples to obtain the density of each fraction.
4. Slot-blot aliquots (5–50 mL, after dilution if necessary) of each fraction onto
Immobilon P membrane and visualize with a carbohydrate stain (see Note 12) (6).
Quantify the results using a densitometer (7). For the radioactive samples cut out
each slot-blot and place in scintillation cocktail for quantitation (see Note 13). Analy-
sis by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) can
be used (see Note 14).
5. Pool the mucin-containing fractions located at densities between 1.30 and 1.55 g/mL.
232 Corfield et al.
3.3.2. Gel Filtration (
see
Notes 11 and 15)
1. Make up samples in 10 mM Tris-HCl, pH 8.0, or 4 M guanidine hydrochloride/PBS buffer
to give concentrations of 1–5 mg/mL of protein or by radioactivity (e.g., >5000 cpm), and
load onto columns of Sepharose CL-2B. Elute the column with the same buffer and col-
lect fractions (1–5 mL).
2. Identify mucin-containing fractions as described in Subheading 3.3.1., step 4 (see Notes 12–14).
3. Pool the mucin-containing fractions identified in excluded or included volumes.
3.3.3. Agarose Gel Electrophoresis
and Vacuum Blotting (
see
Notes 16 and 17)
1. Mix samples containing 10–500 mg mucin or >10,000cpm with 50 mL sample buffer and
load onto horizontal 0.8–1% agarose gels. Run Rainbow markers and IgM as migration
markers (see Note 17).
2. Run the gels at 20 V for 18 h, or 20 mA for 14 h at room temperature.
3. Remove the gels after electrophoresis and stain directly using Coomassie blue stain (see
Note 18) or submit to vacuum blotting. Alternatively, dry the gels and use immediately
for autoradiography or fluorography to visualize the radioactive mucins (see Note 19 and
Chapter 20).
4. Blot gels onto Immobilon P membranes using a standard apparatus in vacuum-blotting
buffer for 2 h at 40 mbar. The success of the transfer can be visualized immediately if
Rainbow markers are included on the gels.
5. Probe the blotted membranes with chemical stains (e.g., PAS), lectin conjugates or anti-
bodies using standard techniques for visualization (see Note 13). Radioactive compo-
nents can also be detected on the same blots (see Note 19).
3.3.4. Concentration of Mucin Samples After Purification (
see
Note 20)
1. Dialyze the samples against 4–5 changes of 5 L of distilled water or against two changes
of 1 L of 4 M guanidine hydrochloride. Salt free samples can be freeze dried to concen-
trate (see Note 20).
2. Dialyze the samples against high molecular weight polyethylene glycol 20,000 (30%) in
distilled water or 4 M guanidine hydrochloride. Samples for ion-exchange can then be
dialyzed against suitable urea containing buffers with 0.05% CHAPS.
3. Mix a solution containing mucin (1–5 mg or >10,000cpm) with 4 vols of precipitation
buffer cooled to –70°C and leave for 45 min at –70°C. Return to room temperature for
centrifugation at 12,000g for 20 min and collect the pellet.
3.3.5. Identification and Removal of Proteoglycans (
see
Notes 21 and 22)
1. Mix samples containing 0.5–2.0 mg of mucin or >10,000 cpm with the followng:
a. Chondroitinase ABC (5 U/mL) and incubate for 16 h at 37°C in incubation buffer
(Subheading 2., item 18a).
b. Hyaluronidase (10 mg/mL) and incubate for 16 h at 37°C in incubation buffer (Sub-
heading 2., item 18b).
c. Heparinase II and III (100 mU of each enzyme) and incubate for 16 h at 37°C in
incubation buffer (Subheading 2., item 18c).
Carry out control incubations under the same conditions without enzyme.
2. Stop the incubations by addition of 1-mL of 10 mI Tris-HCl, pH 8.0, and load the prod-
ucts onto columns of Sephadex G100, eluting with the same buffer and collecting 1-mL
fractions.
Metabolic Labeling Methods 233
3. Test the individual fractions for radioactivity or carbohydrate by slot-blotting or by colo-
rimetric analysis (see Note 22). Analysis by SDS-PAGE can also be used (see Note 14).
4. Notes
1. A protease inhibitor cocktail is needed to avoid the degradation of mucins by bacterial
enzymes and in cell homogenates. STI and PMSF are the most important for colonic
tissue.
2. We have evidence that mucins will be degraded during dialysis, and other prolonged
procedures under circumstances of insufficient protease inhibition (19). During dialysis
always be sure to use adequate precautions against degradation. It is convenient to dia-
lyze against 4–6 M guanidine hydrochloride at 4°C, which will inhibit nearly all enzy-
matic activities. Dialysis against specific protease inhibitors such as PMSF and STI is
also very expensive. Note that the presence of guanidine hydrochloride will not irrevers-
ibly eliminate the degrading enzymes by itself. On removal of the guanidine hydrochlo-
ride, e.g., by dialysis or gel filtration, the enzymes may be reactivated.
3. In radiolabeling experiments, the total amount of mucin is often small, and significant
losses owing to nonspecific adsorption onto plastic and glass vessels, silicone rubber, and
dialysis tubing may occur. Treatment of all vessels and tubing with 1% Triton in PBS
before use improves yields.
4. The continuous labeling techniques do not use an incubation period in which the radioac-
tive label is depleted. The commonly used label glucosamine is not a normal component
in standard media and can be regarded as a supplement. The pulse/chase protocol always
starts with a 30- to 45-min period during which the compound chosen as precursor is first
(partially) depleted from the medium. After the depletion period, the label is added to the
same medium and incubation proccedes with no medium change.
5. The choice of radioactive precursor is important. Radioactive glucosamine is most com-
monly used because it is incorporated into N-acetyl-D-glucosamine, N-acetyl-D-galac-
tosamine, and the sialic acids, major monosaccharide components of mucins. In tissues
other than liver, labels such as mannose and fucose may be randomized to other monosac-
charides before they are transferred to glycoproteins.
6. The metabolic rate of the cells should be considered for optimum labeling with the radio-
active precursor during continuous labeling cultures. The type of isotope will govern the
amount to be added, typically (
14
C)- and (
35
S)- precursors in the range 185–1850 kBq/
experiment and (
3
H) precursors in the range 370–1850 kBq/experiment. Short term label-
ing of 2-4h may not result in labelling of secreted material and could require higher doses
of radioactive precursor (1.85–3.7 MBq/experiment). Longer labeling periods may reflect
synthesis, catabolism and recycling of glycoproteins. Dual labeling experiments with,
e.g., (
35
S) and (
3
H) need to be planned so that the relative incorporation of each isotope is
readily detectable in the isolated product; thus, consideration of Notes 5 and 7 is neces-
sary. Organ culture experiments should be controlled by histochemical criteria to ensure
the integrity of the tissue during the incubation period. Diseased tissue may show signs of
degradation during acceptable culture times for normal samples.
7. In continuous-labeling cultures, increased incorporation of radioactive precursors may be
achieved by reduction of the concentration of the same nonlabeled compound in the
medium (monosaccharides or amino-acids) for the labeling period as described for the
pulse/chase cultures (see Notes 8 and 9). However, this should be balanced against any
changes in the growth of the cells or tissue under these “depleted” conditions and for the
total culture period.
234 Corfield et al.
8. For the labeling of each cell type use 5 µCi (185 kBq) (
35
S) amino acids or (
35
S) sulfate/
cm
2
cell culture. All cell cultures can be labelled in an air incubator with 5% CO
2
or in an
airtight container flushed with 5% CO
2
/95% O
2
and placed in a 37°C incubator.
a. Optimal labeling conditions for LS147T cells (4 cm
2
wells are best): Use only
preconfluent or freshly confluent cultures because cells will detach progressively from
the plastic after they reach confluence, and labeling efficiency deteriorates rapidly after
confluency (12). In addition cells with a low passage number must be used owing to
deterioration of the labelling efficiency at later passages. An aliquot of 20 µCi (740
kBq) is added to each tissue culture well in 250 µL of depletion medium. Pulse labeling
is performed for either 30 min ([
35
S] amino acids ) or 60 min ([
35
S] sulfate).
b. Optimal labeling conditions for Caco-2 (F25 flasks, 25 cm
2
): Use cells that are at
least 5–7 d confluent, which will give the most efficient labeling (12). An aliquot of
125 µCi (4625 kBq) is added to 1 mL of depletion medium in each 25 cm
2
culture
flask. Pulse labeling times are identical to LS174T cells.
c. Optimal labeling conditions for A431 are identical to those for Caco-2, but labeling
efficiency is highest in preconfluent cultures (Van Klinken, Einerhand, and Dekker,
unpublished results)
9. For each of the following labels used in pulse/chase labeling experiments: [
35
S]methionine/
[
35
S]cysteine (i.e., Promix™), [
3
H]threonine, [
35
S]sulfate, and [
3
H]galactose—100 µCi (3700
kBq) of label is added per tube containing one tissue segment. Metabolic labeling has
been performed for each of the following GI tissues of human, rat and mouse (13–17):
stomach, gallbladder (not in rat), duodenum, jejunum, ileum, caecum, ascending colon,
transverse colon, descending colon, and sigmoid colon. For Promix and [
3
H]threonine,
pulse times are as follows: 30 min except for stomach (15 min) and for ileum (60 min).
Stomach tissue is very efficiently labelled with labelled amino acids, whereas labeling of
the ileum appears to be very inefficient. The pulse time for (
35
S)sulfate and (
3
H)galactose
are: 60 min except for stomach and sigmoid colon (both 30 min). Again ileum is very
inefficiently labeled with the latter compounds. The origin(s) of the differences in label-
ing efficiency among these organs is not known. It is essential that incubation commences
within 10 min of removal from the body.
10. The intestinal mucins are present as adherent gels, which are not always soluble in con-
centrated guanidine hydrochloride alone (18). To achieve complete solution, reduction,
and alkylation are necessary. This leads to the formation of mucin subunits which can be
identified on agarose gel electrophoresis (8).
11. The sequence of purification steps in mucin purification is significant. If density gradient
centrifugation is followed by gel filtration, any lower molecular weight subunits or deg-
radation products may be identified.
12. The use of a general carbohydrate stain is useful to detect mucins on slot blots. The peri-
odic acid Schiff stain (PAS) can be used and sensitivity is improved on the membranes as
salt is eliminated (see Note 13). Lectins can also be used as general probes. Wheat germ
agglutinin–horse radish peroxidase conjugate has been found to be a satisfactory and
sensitive probe for mucins on slot blots (20).
13. Owing to high salt concentrations in density gradient centrifugation experiments, many
colorimetric assays and some radioactive scintillation cocktails are inefficient. Extensive
dialysis of each fraction may allow colorimetric assays to be performed, but with small
amounts of metabolically labeled material this results in significant losses (see Note 3).
The slot blotting technique (Note 12) is more reliable and sensitive for colorimetric and
radioactive detection.
Metabolic Labeling Methods 235
14. After dialysis of the guanidine hydrochloride containing fraction of the CsCl density gradi-
ent against water, the fractions can also be analysed by SDS-PAGE (13–17,19). Typically,
4% SDS-PAGE gels are used. These gels can be PAS stained, or Western blotted with
specific antibodies to detect the mucins (see also Chapter 20). If higher polyacrylamide
concentrations are used (7.5% or 3–10% gradient gels) double staining of the gels with PAS
and Coomassie Blue will clearly show the contaminating nonmucin proteins within each
fraction. Alternatively, radioactively labeled mucins can be visualized directly by similar
analysis on SDS-PAGE followed by fluorography, as described in Chapter 20.
15. Gel filtration is the most rapid and convenient method to obtain a mucin-enriched fraction
from crude culture samples for comparative studies (1,2). It is also a starting point for prepa-
ration of native mucins for further purification and analysis (see Note 11). Automated fast-
protein liquid chromatography (FPLC) systems can also be used to analyze samples in the
same way, but are not as flexible in preparation of larger fractions of mucin.
16. The separation of mucins on agarose gel electrophoresis allows the largest mucin mol-
ecules to be analyzed, whereas SDS-PAGE systems may show incomplete migration of
the sample into the gels (8).
17. Markers for agarose gel electrophoresis reflect the separation of molecules on the basis of
their size and charge. This is in contrast to the normal conditions used for proteins and
some glycoproteins on SDS-PAGE. Accordingly, the use of markers on agarose gel elec-
trophoresis can give only an estimate of relative migration and not of molecular size.
18. Protein stains for mucins are usually very poor. Coomassie blue and silver stains fre-
quently give negative results. Chemical stains for carbohydrate, lectin conjugates, or spe-
cific antibodies are the most useful.
19. If the mucins analysed by blotting procedures are radioactive, it is possible, after probing the
blot with antibodies or lectins, to subject the membrane to autoradiography to colocalize the
radioactive components. In this way a dual identification of alleged mucin bands can be made.
20. When possible, samples of mucin should be kept in solution, preferably in 4 M guanidine
hydrochloride. Desalting and/or freeze-drying may result in the production of a residue that
cannot be resolubilized. Concentration of mucin samples may be difficult and where samples
are treated by such methods assessment of mucin loss is advisable. Mild precipitation meth-
ods at reduced temperature or with specific antibodies for smaller samples are best but
require suitable controls for efficiency.
21. The proportion of proteoglycan in colonic cell and tissue samples is normally low but in
cases of cell transformation or selection of subclones (21) care must be taken to control high
molecular weight material with a buoyant density in the range of 1.35–1.60 g/mL for the
presence of proteoglycans. In metabolic labeling experiments the presence of cells having a
high turnover rate for proteoglycans, e.g., fibroblast hyaluronan synthesis, may significantly
add to the proportion of labeled material isolated in “mucin” fractions. Both of these situa-
tions require the analysis of suspected mucin products using enzymatic degradation.
22. The assay of carbohydrate breakdown products of proteoglycan degradation must be car-
ried out using liquid assay systems because these products are of low molecular weight
and will not be detectable using membrane-blotting techniques. Assay for total carbohy-
drate or hexosamine is appropriate.
References
1. Corfield, A. P., Warren, B. F., Bartolo, D. C. C., Wagner, S. A., and Clamp, J. R. (1992)
Mucin changes in ileoanal pouches monitored by metabolic labelling and histochemistry.
Brit. J. Surgery 79, 1209–1212.
236 Corfield et al.
2. Probert, C. S. J., Warren, B. F., Perry, T., Mackay, E. H., Mayberry, J. F., and Corfield, A.
P. (1995) South Asian and European colitics show characteristic differences in colonic
mucus glycoprotein type and turnover. Potential identification of a lower risk group for
severe disease and cancer. Gut 36, 696–702.
4. Forstner, J. F. and Forstner, G. G. (1994) Gastrointestinal mucus, in Physiology of the
Gastrointestinal Tract. (Johnson, L. R., eds.), Raven Press, New York, pp. 1245–1283.
5. Jass, J. R. and Roberton, A. M. (1994) Colorectal mucin histochemistry in health and
disease: A critical review. Pathology International. 44, 487–504.
3. Vavasseur, F., Dole, K., Yang, J., Matta, K. L., Corfield, A. P., Myerscough, N., Paraskeva,
C., and Brockhausen, I. (1994) O-glycan biosynthesis in human colonic cells during pro-
gression to cancer. Eur. J. Biochem. 222, 415–424.
7. Thornton, D. J., Carlstedt, I., and Sheehan, J. K. (1994) Identification of glycoproteins on
nitrocellulose membranes and gels, in Basic Protein and Peptide Protocols, vol. 32
(Walker, J. M., eds.), Humana Press, Totowa, pp. 119–128.
8. Thornton, D. J., Holmes, D. F., Sheehan, J. K., and Carlstedt, I. (1989) Quantitation of mu-
cus glycoproteins blotted onto nitrocellulose membranes. Anal. Biochem. 182, 160–164.
9. Thornton, D. J., Howard, M., Devine, P. L., and Sheehan, J. K. (1995) Methods for sepa-
ration and deglycosylation of mucin subunits. Anal. Biochem. 227, 162–167.
6. Corfield, A. P., Clamp, J. R., Casey, A. D., and Paraskeva, C. (1990) Characterization of a
sialic acid-rich mucus glycoprotein secreted by a premalignant human colorectal adenoma
cell line. Int. J. Cancer 46, 1059–1065.
10. Carlstedt, I. and Sheehan, J. K. (1984) Macromolecular properties and polymeric structure
of mucus glycoproteins, in Mucus and mucosa, vol. 109, Pitman, London, pp. 157–172.
11. Thornton, D. J., Devine, P. L., Hanski, C., Howard, M., and Sheehan, J. K. (1994) Identi-
fication of two major populations of mucins in respiratory secretions. Am. J. Respir. Crit.
Care Med. 150, 823–832.
12. Van Klinken, J W., Oussoren, E., Weenink, J J., Strous, G. J., Büller, H. A., Dekker, J.,
and Einerhand, A. W. C. (1996) The human intestinal cell lines Caco-2 and LS174T as
models to study cell-type specific mucin expression. Glycoconjugate J. 13, 757–768.
13. Tytgat, K. M. A. J., Büller, H. A., Opdam, F. J. M., Kim, Y. S., Einerhand, A. W. C., and
Dekker, J. (1994) Biosynthesis of human colonic mucin: Muc2 is the predominant secre-
tory mucin. Gastroenterology 107, 1352–1363.
14. Dekker, J., Van Beurden-Lamers, W. M. O., and Strous, G. J. (1989) Biosynthesis of
gastric mucus glycoprotein of the rat. J. Biol. Chem. 264, 10,431–10,437.
15. Dekker, J. and Strous, G. J. (1990) Covalent oligomerization of rat gastric mucin occurs in
the rough endoplasmic reticulum, is N-glycosylation dependent, and precedes initial O-
glycosylation. J. Biol. Chem. 265, 18,116–18,122
16. Van Klinken, B. J. W., De Bolos, C., Büller, H. A., Dekker, J., and Einerhand, A. W. C.
(1997) Biosynthesis of mucins (MUC2-6) along the longitudinal axis of the gastrointesti-
nal tract. Am. J. Physiol. 273, G296–G302.
17. Van Klinken, B. J. W., Dekker, J., Van Gool, S. A., Van Marle, J., Büller, H. A., and
Einerhand, A. W. C. (1998) MUC5B is the prominent mucin in human gallbladder and is
also expressed in a subset of colonic goblet cells. Am. J. Physiol. 274, G871–G878.
18. Asker, N., Baekstrom, D., Axelsson, M. A. B., Carlstedt, I., and Hansson, G. C. (1995) The
human MUC2 mucin apoprotein appears to dimerize before O-glycosylation and shares
epitopes with the ‘insoluble’ mucin of rat small intestine. Biochem. J. 308, 873–880.
19. Dekker, J., Van Beurden-Lammers, W.M.O., Oprins, A., and Strous, G.J. (1989) Isolation
and structural analysis of rat gastric mucus glycoprotein suggests a homogenous protein
backbone. Biochem. J. 260, 717-723.
Không có nhận xét nào:
Đăng nhận xét